Research Expert: Sarah Overall
  • Published: Jun 2025
  • Pages: 150
  • SKU: IRTNTR76165

  • Latest News- Ursodeoxycholic Acid Market: Synthetic is expected to lead the Type segment during 2025-2029

    The Ursodeoxycholic Acid Market is being driven by Rise in number of liver transplants

    The Ursodeoxycholic Acid Market is expected to grow at a CAGR of 12.9% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 550.4 million. Ursodeoxycholic acid (UDCA), a bile acid, holds significant value in the therapeutic arena for managing various liver disorders and diseases, including Primary Biliary Cholangitis (PBC) and gallstone dissolution. The global ursodeoxycholic acid market is witnessing robust growth, primarily driven by the increasing acceptance of combination therapies in the treatment of liver diseases. These therapies involve the concurrent administration of two or more medications to amplify treatment efficacy and optimize patient outcomes. In the context of liver disorders, the synergistic use of UDCA with immunosuppressants or steroids has been clinically proven to mitigate disease progression and alleviate symptoms more effectively than monotherapy. 

    Get more information on Ursodeoxycholic Acid Market by requesting a sample report

    Which Factors Are Causing a Surge in Market Growth?

    The market is segmented based on

    • Type
      • Synthetic
      • Extraction
    • Application
      • Pharmacy products
      • Health products
    • Distribution Channel
      • Hospital pharmacies
      • Retail pharmacies
      • Online pharmacies
    • Geography
      • North America
        • Canada
        • US
      • Europe
        • Germany
        • UK
        • France
        • Italy
      • Asia
        • China
        • India
        • Japan
      • Rest of World (ROW)

      According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

      • Rise in number of liver transplants
      • Increasing incidence of primary sclerosing cholangitis and associated diseases
      • Expansion of indications for UDCA

      However, the market also witnesses some limitations, which are as follows:

      • Expiry of patents on branded drugs leading to competition with manufacturers of generics
      • Adverse effects and safety concerns associated with UDCA
      • Limited awareness and underdiagnosis of liver diseases

      Benefits of Buying Global Ursodeoxycholic Acid Market Research Report by Technavio

      Rich Experience: 20+ years leading global market research, trusted insights across industries.

      Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

      Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

      Market Scope in Ursodeoxycholic Acid Market Research Report

      Market Scope

      Report Coverage

      Details

      Page number

      205

      Base year

      2024

      Historic period

      2019-2023

      Forecast period

      2025-2029

      Growth momentum & CAGR

      Accelerate at a CAGR of 12.9%

      Market growth 2025-2029

      USD 550.4 million

      Market structure

      fragmentation

      YoY growth 2024-2025(%)

      11.2

      Key countries

      US, Germany, UK, China, Canada, India, Brazil, France, Japan, and Italy

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Find out which segment is leading the market by accessing the free PDF report

      Research Analysis Overview

      The Ursodeoxycholic Acid Market encompasses various applications in the treatment and management of liver diseases. Key diagnostic tools include bile acid sequestrants, magnetic resonance imaging (MRI), computed tomography (CT), liver ultrasound, endoscopic ultrasound, liver stiffness measurement, and liver elastography. Therapeutic interventions include liver fibrosis treatments like stem cell therapy, gene therapy, antiviral agents, nutritional supplements, and lifestyle modifications such as weight management, physical activity, and dietary changes. Additionally, alcohol consumption and smoking cessation are crucial factors. The market involves stakeholders like biotechnology industry, clinical research organizations, contract manufacturing organizations, supply chain management, distribution networks, marketing and promotion through digital marketing and social media, medical devices, diagnostic kits, and therapeutic devices.

      Market Research Overview

      The Ursodeoxycholic Acid (UDCA) market is a significant segment of the global pharmaceuticals industry, focusing on companies and research organizations involved in the development and manufacture of generic and non-generic drugs, including veterinary medicines. According to Technavio's market analysis, the healthcare sector's overall size is determined by the consolidated revenue generated by providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the expansion of the pharmaceuticals market include the increasing elderly population – by 2050, approximately one-quarter of the US and European populations are projected to be over 60 years old – and the subsequent rise in prevalence of conditions such as primary biliary cholangitis, primary sclerosing cholangitis, liver disease, hepatic encephalopathy, bile acid-related disorders, hepatocellular carcinoma, and drug-induced liver injury. UDCA, as a bile acid, plays a crucial role in treating various liver-related conditions, making it a vital component of the pharmaceuticals market's growth trajectory.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.


      Contacts

      Technavio Research
      Jesse Maida
      Media & Marketing Executive
      US: +1 844 364 1100
      UK: +44 203 893 3200
      Email: media@technavio.com
      Website: www.technavio.com/

      Read News Read Less
      Interested in this report?
      Get your sample now!

    Safe and Secure SSL Encrypted

    Technavio

    • 2500 USD

    [5 reports/month/user]

    • 5000 USD

    close
    • Basic Plan [5000 USD/Year]:

      Single User
      Download 5 Reports/Month
      View 100 Reports/Month
      Add upto 3 Users at 625 USD/user

    • Teams Plan [7500 USD/Year]:

      5 User
      Download 5 Reports/Month/User
      View 100 Reports/Month/User
      Add upto 30 Users at 500 USD/user

    *You can upgrade to Teams plan at Subscription page

    close
    • Single:

      One user only.
      Quick & easy download option

    • Enterprise:

      Unlimited user access (Within your organization).
      Complimentary Customization Included

    *For Enterprise license, go to checkout page

    Technavio Get the report (PDF) sent to your email within minutes.